Protection against <i>Borreliella burgdorferi</i> infection mediated by a synthetically engineered DNA vaccine
Ghiabe-Henri Guibinga, Bikash Sahay, Heather Brown, Neil Cooch, Jing Chen, Jian Yan, Charles C. Reed, Meerambika Mishra, Bryan S. Yung, Holly Pugh, Katherine Schultheis, Rianne Esquivel, David B. Weiner, Laurent Humeau, Kate E. Broderick, Trevor R.F. Smith
Abstract
burgdorferi bacterial challenge. We also assessed intradermal (ID) delivery of pLD1 in Hartley guinea pigs, demonstrating the induction of robust and durable humoral immunity that lasts at least 1 year. We provide evidence of the potency of pLD1 by showing that antibodies targeting the OspA epitopes which have been associated with protection are prominently raised in the immunized guinea pigs. The described study provides the basis for the advancement of pDL1 as a potential vaccine for Lyme disease control.